^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KMT2C mutation

i
Other names: MLL3, KMT2C, Lysine Methyltransferase 2C, Histone-Lysine N-Methyltransferase 2C, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 3, Lysine (K)-Specific Methyltransferase 2C, Histone-Lysine N-Methyltransferase, H3 Lysine-4 Specific, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 3, Histone-Lysine N-Methyltransferase MLL3, Lysine N-Methyltransferase 2C, ALR-Like Protein, KLEFS2
Entrez ID:
Related biomarkers:
1year
MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma. (PubMed, Blood Cancer J)
TP53 and KMT2C mutations conferred inferior outcome (3-year EFS P < 0.05). Overall, MYC-R lymphomas in CAYA have a molecular profile similar to BL regardless of their high-grade or DLBCL morphology, whereas MYC-non-R has more heterogeneous genetic alterations closer to that of DLBCL.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • KMT2C (Lysine Methyltransferase 2C)
|
TP53 mutation • MYC expression • KMT2C mutation • MYC rearrangement • BCL6 translocation • MLL3 mutation
1year
A Pilot Study Based on the Correlation Between Whole Exome and Transcriptome Reveals Potent Variants in the Indian Population of Cervical Cancer. (PubMed, Indian J Microbiol)
Understanding emerging harmful mutations from an Indian viewpoint is facilitated by our bioinformatics-based, extensive correlation studies of WES analysis. Potentially harmful and new mutations were found in our preliminary analysis; among these ten top mutated genes, KMT2C and CIQTNF were altered in ten cases of CC with an Indian phenotype.
Journal
|
KMT2C (Lysine Methyltransferase 2C)
|
KMT2C mutation
over1year
KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer. (PubMed, Sci Rep)
Meanwhile, KMT2C mutation was associated with higher tumor mutation burden, MSI score, higher levels of immune-associated T cells, neutrophil, and M1-type macrophages. Our study suggested that KMT2C mutation might be a potential positive predictor for CRC immunotherapy.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • KMT2C (Lysine Methyltransferase 2C)
|
KMT2C mutation • MLL3 mutation
over1year
A comprehensive histomolecular characterization of meningioangiomatosis: Further evidence for a precursor neoplastic lesion. (PubMed, Brain Pathol)
The DNA-methylation profile, using a t-distributed stochastic neighbor embedding analysis, evidenced that MAM (pure or associated with meningiomas) clustered in a separate group from pediatric meningiomas. The present results seem to suggest that MAM represents a neoplastic lesion and encourage the further study of similar additional series so that it may be included in a future WHO classification.
Journal
|
KMT2C (Lysine Methyltransferase 2C) • NF2 (Neurofibromin 2)
|
KMT2C mutation • MLL3 mutation
over1year
Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights. (PubMed, Front Oncol)
Monosomy 7's prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression.
Journal
|
PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • KMT2C (Lysine Methyltransferase 2C)
|
PTPN11 mutation • KMT2C mutation • MLL3 mutation
over1year
Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis. (PubMed, Clin Genitourin Cancer)
In conclusion, the ACD-RCC subtype exhibited several distinct clinicopathological and genetic characteristics compared to others RCC subtypes. Further researchs are needed to assess the survival outcome and the genetic characteristics of this subtype.
Retrospective data • Review • Journal
|
KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2)
|
KMT2C mutation • TSC2 mutation
almost2years
Germline variants in early and late-onset Brazilian prostate cancer patients. (PubMed, Urol Oncol)
Our findings contribute to a deeper understanding of the genetic factors associated with PCa susceptibility in different age groups, especially among the Brazilian population. This is the first investigation to explore germline variants specifically in younger Brazilian PCa patients, with high relevance given the genetic diversity of the population in Brazil. Additionally, our work presents evidence of functionally deleterious germline variants within the KMT2C gene among Brazilian PCa patients. The identification of novel and functionally significant variants in the KMT2C gene emphasizes its potential role in PCa development and warrants further investigation.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • KMT2C (Lysine Methyltransferase 2C)
|
KMT2C mutation • MLL3 mutation
almost2years
Assessment of Genetic Stability in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Using Droplet Digital PCR. (PubMed, Int J Mol Sci)
Our droplet digital PCR results showed high sensitivity and accuracy for quantitatively detecting gene mutations, whereas conventional qPCR could not avoid false positives. In conclusion, droplet digital PCR is a highly sensitive and precise method for assessing the expression of mutations with tumorigenic potential for the development of stem cell-based therapeutics.
Journal
|
KMT2C (Lysine Methyltransferase 2C) • BCOR (BCL6 Corepressor)
|
KMT2C mutation
almost2years
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma. (PubMed, Cancer Res Treat)
Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed...Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Journal • Tumor mutational burden • Circulating tumor DNA
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C) • CREBBP (CREB binding protein)
|
TP53 mutation • KMT2D mutation • CREBBP mutation • KMT2C mutation
|
Rituxan (rituximab)
2years
Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer. (PubMed, Front Oncol)
Noteworthy BRAF and ARID2 protein expression decreases detected in patients with their respective mutations. The integration of our analyses furnishes crucial insights into CRC's molecular characteristics, drug responsiveness, and the construction of a four-gene mutation signature for predicting CRC prognosis.
Journal
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • GNAQ (G Protein Subunit Alpha Q) • KMT2C (Lysine Methyltransferase 2C) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • FAT1 (FAT atypical cadherin 1) • ARID2 (AT-Rich Interaction Domain 2) • TGFB1 (Transforming Growth Factor Beta 1) • PI3K (Phosphoinositide 3-kinases)
|
BRAF mutation • GNAQ mutation • AR mutation • KMT2C mutation • MLL3 mutation
2years
Intestinal-Type Adenocarcinoma in Head and Neck: Dissecting Oncogenic Gene Alterations Through Whole Transcriptome and Exome Analysis. (PubMed, Mod Pathol)
This changed the activity of multiple genes/gene clusters, supporting oncogenicity mostly via pathways of signaling, dedifferentiation, proliferation, migration, immune and inflammatory deregulation, indicating a truly epigenetic event as the root cause for the heterogeneous diversity of these enteric types of cancer. The data of this study form the basis for understanding cell fate determination and cellular homeostasis in the normal respiratory mucosa at different anatomic sites and show the contribution of different mucosal components to the etiology/molecular pathology of ITAC.
Journal
|
KMT2C (Lysine Methyltransferase 2C)
|
KMT2C mutation • MLL mutation • MLL3 mutation
2years
Transcriptomic Analysis of Clonal Hematopoiesis in Solid Tumors Reveals Driver Mutation-Specific Patterns of Immune Dysregulation (ASH 2023)
This work demonstrates that while general inflammatory changes are evident at the tumor level with CH, there is a critical need to recognize the nuances of CH-associated immune mechanisms in cancer, which appear to vary by cancer type and CH driver. Ongoing efforts will continue to characterize the TIME of the other TCGA cancers through transcriptomic analysis and in situ histological imaging. This study also provides some early clinical evidence for the selection of KMT2C variants in cancer patients, though more work is needed to understand their clonal dynamics and clinical implications.
IO biomarker • Omic analysis
|
DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2C (Lysine Methyltransferase 2C) • CHI3L1 (Chitinase 3-like 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • KLRC2 (Killer Cell Lectin Like Receptor C2)
|
DNMT3A mutation • ASXL1 mutation • KMT2C mutation • MLL3 mutation